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Major histocompatibility complex (MHC) class II mol-
ecules play a central role in immune responses, and
transcription of this family of genes requires the MHC
class II transactivator (CIITA). CIITA has four promot-
ers, which are transcribed in a tissue-specific manner.
CIITA promoter III is constitutively active in mature
B-lymphocytes. This report now describes the minimal
319-base pair promoter region necessary for maximal
transcriptional activity in B-lymphocytes. Ultraviolet
light and dimethylsulfate in vivo genomic footprinting
analyses reveal five occupied DNA sequence elements
present in intact B-lymphocytes. Functional analysis of
these elements using promoter deletions and site-spe-
cific mutations demonstrates that at least two of the
sites occupied in vivo are critical for transcriptional
activity. In vitro protein/DNA analysis suggests that one
of the sites is a TEF-2-like element and the other is
occupied by a novel transcription activator. In addition,
nuclear factor-1 associates with the promoter both in
vivo and in vitro. In myeloma cell lines, loss of CIITA
transcription correlates with a completely unoccupied
CIITA promoter III. These findings suggest that CIITA
transcription in B-lymphocytes is activated through at
least two strong promoter elements, while loss of expres-
sion in myeloma cells is mediated through changes in
promoter assembly.
Major histocompatibility complex (MHC)1 class II molecules
play a fundamental role in presenting exogenous antigenic
peptides to CD41 helper T lymphocytes (1). These activated
CD41 T cells release stimulatory cytokines that augment the
response of CD81 cytotoxic T lymphocytes (2). Constitutive
expression of MHC class II molecules is restricted to profes-
sional antigen-presenting cells, such as B lymphocytes and
dendritic cells, and can be induced by interferon-g (IFN-g) in
macrophages, endothelial cells, and fibroblasts (3, 4). The MHC
class II family of genes are coordinately regulated at the level
of transcription through a conserved trimeric promoter motif
(3, 5). A major component of this transcription complex was
cloned by genetic complementation of an in vitro mutagenized
MHC class II negative B cell line, RJ2.2.5. This component was
named the MHC class II transactivator (CIITA) and restored
MHC class II cell surface expression in one subgroup of bare
lymphocyte syndrome patient cells (6). CIITA has since been
shown to be a key regulatory molecule in the expression of all
the known genes involved in the MHC class II antigen-present-
ing pathway (6–9). CIITA is required for constitutive expres-
sion of MHC class II on B-lymphocytes (10) and with a few
exceptions, such as in respiratory epithelial cells and dendritic
cells (11, 12), is required for cytokine-induced expression in
other cell types. Mice in which functional CIITA protein was
ablated clearly demonstrated an absolute requirement for CI-
ITA in B cell expression of MHC class II (13). It has been shown
that the CIITA gene has four distinct promoters each transcrib-
ing a unique first exon, which are located within approximately
13 kilobases of DNA (10). The promoters are utilized in a
tissue-specific manner. CIITA expression in dendritic cells is
primarily from promoter I. Promoter III is predominantly used
in B-lymphocytes, while promoter IV is used predominantly in
IFN-g-induced expression. The first exon associated with the B
cell and dendritic cell promoters encodes distinct amino-termi-
nal residues of 24 and 101 amino acids, respectively, while
mRNA from promoters II and IV initiates translation from
within the common exon 2 (10). Promoter II has yet to be
characterized.
The IFN-g-responsive control elements at CIITA promoter
IV were recently characterized (14, 15). Both STAT-1 and
IRF-1 are required at the proximal promoter for full response.
Binding of the USF-1 transcription factor stabilizes STAT-1
binding (15). Initial mapping of the CIITA promoter III re-
vealed that sequences that lie between 2545 and 2113 base
pairs relative to the transcription start site are required for
constitutive expression in B-lymphocytes (16). While this re-
gion of the promoter is not responsive to IFN-g, IFN-g activa-
tion of CIITA promoter III can be observed when an additional
4000 base pairs of upstream DNA are present (16). However,
nothing is known about the specific factors and promoter ele-
ments that control constitutive transcription from CIITA pro-
moter III in B-lymphocytes.
Tight regulation of the expression of MHC class II genes has
been observed during B cell development. MHC class II gene
transcription begins in the pre-B cell stage, is maintained until
B-lymphocytes attain maturity (17, 18), and is down-regulated
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when B-lymphocytes terminally differentiate into plasma cells
(19, 20). CIITA expression is also up-regulated in the pre-B cell
stages and then lost upon terminal differentiation (21, 22). The
mechanisms of activation and repression are unknown. CIITA
promoter III does not contain any cis-acting sequences with
significant homology to B cell activators except a putative
octamer binding site.
In this report, we now characterize the CIITA promoter III
regulatory elements in B-lymphocytes and identify in vivo and
in vitro five occupied sites. Importantly, two of the sites are
absolutely required for CIITA transcription in B-lymphocytes.
One is a TEF-2-like element, while the other represents a
binding site for a novel transcription activator.
EXPERIMENTAL PROCEDURES
DNA Constructs—The CIITA promoter III reporter constructs CI-
ITAp3.1140-Luc and CIITAp3.545-Luc contain the human CIITA pro-
moter III sequences from 21140 to 1123 or 2545 to 1123 base pairs,
respectively, relative to the transcription initiation site. These two
constructs were originally carried in the pGL2-Basic vector and de-
scribed previously as p1300CIITA.Luc and p668CIITA.Luc (16), but for
this study they have been moved into the pGL3-Basic vector (Promega).
Each of the other deletion constructs (namely CIITAp3.319-Luc, CI-
ITAp3.195-Luc, CIITAp3.151-Luc, and CIITAp3.113-Luc) were con-
structed similarly and contain CIITA promoter III sequences from 1123
up to the indicated number on the construct name. All of the mutations
except as specifically noted were carried in the CIITAp3.545-Luc con-
struct. Mutant constructs were derived by the unique site elimination
method (CLONTECH) (23). In the construct CIITAp3.545mtSiteA, the
sequence 59-TTGGCGGGCTCCCA-39 was changed to 59-TTGtCtaGaT-
CCCA-39 (mutations in lowercase boldface type). In CIITAp3.545mtSit-
eB, 59-TTCTTTGCATGT-39 was changed to 59-TTCgTcGacaGT-39.
In the construct CIITAp3.545mtARE-2, 59-TGATGATCCCT-39
was changed to 59-TGATctagaCT-39. In the construct
CIITAp3.545mtARE-1, 59-TTAAGGGAGTGTGGTAA-39 was changed
to 59-TTAAGtctagaTGGTAA-39. In the construct CIITAp3.545mtSiteC,
59-GGAAGTGAAATT-39 was changed to 59-GGAgtcGAcgTT-39. Three
additional constructs with mutations in the activation response ele-
ment-1 (ARE-1) sequence were developed in the pGL2-Basic vector
backbone. The first (pGL2.545mtARE1–2) is in the context of the 2545
base pair promoter, while the second (pGL2.151mtARE1–3) and third
(pGL2.151mtARE1–4) constructs are in the context of the 2151 base
pair promoter. The specific base changes are shown in Table I. All
mutations were confirmed by sequencing. The BSAP expression vector
was cloned by reverse transcription PCR into pCDNA3.1 (InVitrogen)
and confirmed by sequencing.
Cell Lines—Raji is a human Epstein-Barr virus-transformed Bur-
kitt’s lymphoma cell line that constitutively expresses MHC class II
antigens (5). NCI-H929 and U266 are human plasmacytoma cell lines
and were grown in 10% heat-inactivated fetal bovine serum, 2 mM
L-glutamine, and 100 units/ml penicillin and streptomycin. NCI-H929
cells were also supplemented with 0.05 mM 2-mercaptoethanol.
Transient Transfections—Cells were transfected by electroporation
using the Bio-Rad Gene Pulser II apparatus. Cells (1 3 107) were pulsed
with 200 V at a capacitance of 1070 microfarads, and cells were har-
vested after 42 h for luciferase assay. All cell lysates were normalized to
recovered protein concentration with the Bradford protein assay
(Bio-Rad).
UV Irradiation and Dimethylsulfate in Vivo Genomic Footprint-
ing—In vivo methylation of cells with dimethylsulfate and DNA prep-
aration were as described previously (24). In vivo UV irradiation foot-
printing was done essentially as described by Pfeifer and Tornaletti
(25). Briefly, cells were collected by centrifugation at 4 °C and resus-
pended at 1 3 107 cells/ml in Dulbecco’s phosphate-buffered saline.
Cells (1 ml) were spread on a 100-mm plastic dish and exposed to
500–2000 J/m2 UV light (UV Crosslinker; Fisher). After exposure (30–
120 s), the cells were immediately harvested by the addition of an equal
volume of 23 lysis buffer (200 mM EDTA, 120 mM Tris-HCl (pH7.5),
0.2% SDS, 1 mg/ml proteinase K). The DNA was isolated and digested
with HindIII as described for the dimethylsulfate-treated samples. The
DNA (20 mg) was cleaved at cyclobutane pyrimidine dimers as described
previously using 20 units T4 endonuclease V (Epicenter Technologies)
and 5 mg of Escherichia coli photolyase generously provided by A.
Sancar (University of North Carolina). Control in vitro UV-irradiated
DNA samples were obtained by first isolating and purifying the
genomic DNA from untreated cells, dissolving 20 mg of DNA in 100 ml
of buffer (10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA) and spotting the
DNA as 5-ml aliquots on parafilm. UV treatment and processing was as
described for the in vivo treated samples.
The ligation-mediated, polymerase chain reaction-amplified in vivo
genomic footprinting was as originally described (26) and modified by
Wright and Ting (27). The upper strand was revealed by using two
different primer sets, C2E and C2F. The sequence of the primers for
C2E are primer 1 (59-TCAGCTTCCCCAAGGATG-39), primer 2 (59-
AGGATGCCTTCGGATGCCCAGCTC-39), and primer 3 (59-TGCCT-
TCGGATGCCCAGCTCAGAAGCAC-39). The sequence of the primers
for C2F are primer 1 (59-AAACTCTCCCTGCAAGGT-39), primer 2 (59-
TCTCCCTGCAAGGTGGCCCCAAGC-39), and primer 3 (59-CCTG-
CAAGGTGGCCCCAAGCGGTCAGATTTC-39). The lower stand was re-
vealed by two primer sets, C2C and C2G. The sequence of the primers
for C2C are primer 1 (59-AAGAAGTCCCCAGCAGAG-39), primer 2 (59-
TCTGGGCGGAGGGCTATGATACTGGC-39), and primer 3 (59-CG-
GAGGGCTATGATACTGGCCCCATCCTGC-39). The sequence of the
primers for C2G are primer 1 (59-CACCAAATTCAGTCCACAG-39),
primer 2 (59-AGAGGTGTAGGGAGGGCTTAAGGGAG-39), and primer
3 (59-AGAGGTGTAGGGAGGGCTTAAGGGAGTGTG-39).
Nuclear Extract Preparation and Electrophoretic Mobility Shift As-
says—Nuclear extracts were prepared according to Dignam et al. (28).
Gel shift analysis was performed as described previously (29) using
synthetic oligonucleotides and 500 ng of the nonspecific competitor
poly(dI:dC). The ARE-1 oligonucleotide spans from 2151 to 2121 base
pairs of the promoter and is 59-GAGGGCTTAAGGGAGTGTGGTA-
AAATTAGAGG-39. The mutant ARE-1 oligonucleotide contains the
same mutation as in construct CIITAp3.545mtARE-1. The ARE-2 oli-
gonucleotide spans from 266 to 251 of the promoter and is 59-GATC-
CTTGATGATCCCTCACTAGATC-39. The mutant ARE-2 oligonucleo-
tide contains the same mutation as in construct CIITAp3.545mtARE-2.
The site A oligonucleotide spans from 234 to 11 base pairs of the
promoter and is 59-GGCTTAGCTTGGCGGGCTCCCAACTGGT-
GACTGG-39. The site B oligonucleotide spans from 255 to 224 of the
promoter and is 59-TCACTTGTTTCTTTGCATGTTGGCTTAGCTTG-39.
The mutSiteA and mutSiteB oligonucleotides contain the same muta-
tion as in constructs CIITAp3.545mtSiteA and CIITAp3.545mtSiteB,
respectively. The site C oligonucleotide spanned from 2190 to 2157
base pairs of the promoter relative to the transcription initiation site
and is 59-GTCCACAGTAAGGAAGTGAAATTAATTTCAGAG-39. The
consensus NF-1 oligonucleotide is 59-TTTTGGATTGAAGCCAATAT-
GATAA-39 (30); the consensus PU.1 oligonucleotide is 59-GGGCTGCT-
TGAGGAAAGTATAAGAAT-39 (31); the consensus BSAP oligonucleo-
tide (BSAP.CD19) is 59-CCGCAGACACCCATGGTTGAGTGCCCTCC-
AGGCCC-39 (32). The consensus TEF-2 oligonucleotide is 59-
GATCCTTAGGGTGTGGACCA-39 (33). Unlabeled oligonucleotide
competitors were used in a 50–100-fold molar excess.
Semiquantitative Reverse Transcription PCR—Cytoplasmic RNA
was prepared from 1–5 3 107 cells using the RNeasy System (Qiagen).
RNA (500 ng) was reverse transcribed using the cDNA Cycle kit (In-
Vitrogen) and resuspended in 20 ml of H2O. The number of PCR cycles
that produced a linear phase of amplification for each product was
empirically determined. Semiquantitative PCR was performed in the
linear phase of amplification using 0.5, 1.0, and 2.0 ml of the cDNA for
each primer pair. Each reaction was done in the presence of 2.5 mM
MgCl2, 0.5 mM each dNTP, 1 mM each primer, 2 units of Taq DNA
polymerase (Life Technologies), and 2 mCi of [a-32P]dCTP in a total
volume of 20 ml.
RESULTS
The First 319 Base Pairs of CIITA Promoter III Are Sufficient
for Transcriptional Activity in B-lymphocytes—The CIITA pro-
moter III has been shown to be constitutively active in B-
lymphocytes (10). To define the functional regions of the pro-
moter, a series of progressive 59 deletions of CIITA promoter III
fused to the luciferase reporter gene were constructed and
transiently transfected into the B cell line Raji. Constructs
containing 1140, 545, or 319 base pairs of the promoter includ-
ing the first 123 base pairs of 59-untranslated sequences exhibit
similar high levels of luciferase activity (Fig. 1). Additional
upstream sequences spanning 7000 base pairs of promoter III
do not further enhance transcriptional activity (16). This indi-
cates that the first 319 base pairs of CIITA promoter III are
sufficient for transcriptional activation in B-lymphocytes.
Deletion of the region from base pair 2319 to 2195 leads to
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a 40% decrease in transcriptional activity, which suggests the
presence of a positive acting element(s) in this 124-base pair
region. Deletion of base pairs 2195 to 2151 does not alter
activity. However, deletion of the region between base pairs
2151 and 2113 greatly diminishes activity, to only 20% of that
observed with the full-length promoter. This suggests the pres-
ence of a second positive element in this 38-base pair region.
Similar results were obtained by transient transfections into
the Namalwa B cell line (data not shown).
In Vivo Genomic Footprinting Analysis in B-lymphocytes De-
tects Multiple Protein/DNA Interactions—In vivo genomic foot-
print analysis of promoters has been invaluable in the visual-
ization of protein/DNA interactions within the physiologically
relevant setting of the intact cell. This technique was exploited
to directly identify occupied DNA elements present in the CI-
ITA promoter. In Raji B cells both strands of the promoter were
analyzed from 169 to 2319 base pairs using dimethylsulfate
(DMS) as the modifying agent (Fig. 2A, summarized in Fig. 3).
Close association of transcription factors in vivo with DNA can
inhibit or enhance DMS methylation of guanine residues. The
resulting pattern of methylation is resolved and compared with
the pattern observed when the proteins are removed prior to
DMS treatment. Analysis of the upper strand reveals seven
very strong protections clustered between base pairs 2142 and
2133 (Fig. 2A, lanes 2 and 4 compared with lanes 1 and 3).
These contacts map within the strong activation domain func-
tionally defined in Fig. 1 between base pairs 2151 and 2113.
For ease of discussion, this element will be defined as ARE-1.
ARE-1 does not contain guanine residues on the lower strand;
thus, DMS cannot reveal interactions on the lower strand (Fig.
2B, lanes 5 and 6). A second region of in vivo protein/DNA
interaction is observed between base pairs 264 and 256, and is
designated activation response element-2 (ARE-2). A single
strong enhancement and a partial protection are detected on
the upper strand (lanes 1 and 2), while the lower strand dis-
plays three very strong protections (lanes 7 and 8). In addition
to these two obvious domains of in vivo binding, three weaker
sites of interaction were detectable. A cluster of five contacts
designated site A is found between 218 and 227, correspond-
ing to a sequence with homology to the NF-1 transcription
factor binding site. Two partial protections are observed on the
upper strand (lanes 1 and 2), while the lower strand displays
two weak enhancements and a partial protection (lanes 7 and
8). A second cluster of contacts, site B, is located at a putative
octamer-binding site homology (base pairs 245 to 238) and is
visualized as a single protected residue on the upper strand
flanked by a partial protection and weak enhancement on the
lower stand. Finally, a single protection is observed at position
2181 on the upper strand (lanes 3 and 4) and is designated site
C. Protections were not detected on either strand upstream of
base pair 2195, and only two isolated weak enhancements
were observed at base pairs 2226 and 2291.
In vivo footprinting with DMS is limited to analysis of gua-
nine residues, which may allow some interactions to escape
detection. In order to expand the effective analysis of interac-
tions on CIITA promoter III, we established in vivo genomic
footprinting using UV light as the modifying agent in place of
DMS. Ultraviolet light induces the formation of pyrimidine
dimers that can be subsequently converted into double strand
DNA breaks. Studies on the PKG1, JUN, PCNA, and FOS gene
promoters have demonstrated suppression or enhancement of
UV photoproduct formation associated specifically with known
sites of in vivo protein/DNA interaction (34, 35). Analysis of
CIITA promoter III demonstrates two strong photoproduct en-
hancements on the lower DNA strand at the ARE-1 element
(Fig. 2B, lane 6 versus lane 4). This is revealed by the more
intense signal in vivo at these two pyrimidine pairs compared
with the neighboring pyrimidine pairs at similar or lower doses
of UV light. This confirms the strong in vivo protections that
were detected by DMS on the upper strand and validates the
usefulness of the technique. A second cluster of three very
strong photoproduct enhancements is located between base
pairs 2183 and 2172, corresponding to the single DMS en-
hancement detected on the upper strand at site C. This con-
firms that site C is a site of in vivo protein binding. In sum-
mary, the in vivo footprinting analyses identified five sites of
protein/DNA interaction within the first 183 base pairs of the
promoter (Fig. 3).
Differentiation of B-lymphocytes into plasma cells is accom-
panied by suppression of MHC class II gene expression (36). In
the single plasmacytoma cell line examined to date, CIITA
expression was down-regulated, and introduction of CIITA res-
cued MHC class II expression (37). However, studies of other
plasmacytoma cell lines have identified some lines that weakly
express MHC class II (38). This may be due to the state of
differentiation of the transformed cell lines. Two different plas-
macytoma cell lines were examined to determine the level of
CIITA expression and if in vivo protein/DNA interactions at the
CIITA promoter were altered. One cell line, NCI-H929, has no
detectable MHC class II DRA or CIITA mRNA (Fig. 4A, lanes
7–9). In contrast, the U266 plasmacytoma cell line has low
levels of both (lanes 10–12) compared with the B cell lines Raji
and IM9 (lanes 1–6). When examined by DMS in vivo genomic
footprinting, CIITA promoter III was completely bare of all in
vivo protein/DNA interactions in the CIITA-negative NCI-
H929 cell line (Fig. 4B). In contrast, in the low CIITA-express-
ing cell line U266, interactions were detected at the ARE-1,
ARE-2, site A, and site B elements, which were indistinguish-
able from those observed in the Raji B cell line. Only site C
binding was diminished in the U266 cells when examined by
either DMS (Fig. 4B) or UV in vivo footprinting (data not
shown). These findings indicate that suppression of CIITA
transcription in U266 cells is mediated through the down-
regulation of activity of a preformed promoter complex. How-
ever, complete transcriptional repression, which occurs late in
plasma cell differentiation and was observed in NCI-H929 cells
is accompanied by complete disassembly of the CIITA promoter
complex.
ARE-1 and ARE-2 Are Critical for Transcriptional Activi-
FIG. 1. Two activation domains are sufficient for transcrip-
tional activity of CIITA promoter III in Raji B cells. CIITA pro-
moter III deletion constructs fused to the reporter gene luciferase were
transiently transfected into Raji B cells. Two positive acting domains
have been detected, one in the region 2319 to 2195 base pairs and
another in the region 2151 to 2113 base pairs. The luciferase activity
of cell extracts was normalized either to b-galactosidase expressed from
a co-transfected control plasmid or to protein content. The results
shown here is an average of 14 experiments, and error bars represent
the mean 6 S.E. Within each experiment, CIITAp3.545-Luc activity
was normalized to 100.
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ty—To determine the functional importance of the newly iden-
tified in vivo binding sites, we prepared site-specific mutations
of the sequences where protein/DNA interactions were detected
and assayed these mutations for effects on transcriptional ac-
tivity (Fig. 5). All of the mutations were analyzed in the context
of the 545-base pair CIITA promoter transiently transfected
into the Raji B cell line.
Mutation of the ARE-1 region significantly lowered tran-
scriptional activity to 25% of wild type activity (lane 1 versus
lane 2). The reduction in activity closely parallels the loss of
activity observed when the entire 38-base pair region was
deleted (Fig. 1, CIITAp3.151-Luc versus CIITAp3.113-Luc). To-
gether, these findings indicate that the ARE-1 element is a
critical transcriptional activator in B cells. Mutation of the in
vivo occupied ARE-2 element from base pair 257 to 261 nearly
abolished transcriptional activity, indicating that it is abso-
lutely critical for transcription (lane 3). The dramatic effect of
this mutation was confirmed by testing the ARE-2-mutated
promoter in another reporter vector. The significance of the
weak in vivo binding activities detected at site A, site B, and
site C were also tested by altering 4 or 5 base pairs at the center
of each footprint. Transcriptional activity was not effected by
mutation of any of the three sites (lanes 4–6). In order to
determine if site A, site B, or ARE-2 functioned cooperatively or
synergistically, combinations of mutations were constructed
and tested. In each construct, only mutation of ARE-2 altered
transcription (lanes 7–9). Site C was also mutated in combina-
tion with the neighboring ARE-1 element. Loss of the site C
binding site did not further decrease activity compared with
the mutation of ARE-1 alone (lane 10 versus lane 2). These
findings indicate that the primary elements responsible for
CIITA promoter III activity are ARE-1 and ARE-2.
ARE-1 Is a TEF-2-like Element—Characterization of the fac-
tor(s) bound to the ARE-1 and ARE-2 elements was initiated
with a series of in vitro protein/DNA binding studies utilizing
the electrophoretic mobility shift assay and DNA sequences
FIG. 2. In vivo genomic footprinting
of the CIITA promoter III reveals
multiple protein/DNA interactions in
intact B-lymphocytes. A, the Raji B cell
line was analyzed using four different
primer sets to display the first 321 base
pairs of the promoter. The first lane of
each pair (lanes 1, 3, 5, and 7) shows the
guanine residues in the control in vitro
methylated DNA. Lanes 2, 4, 6, and 8
show the in vivo methylated DNA sam-
ples. Elements are indicated on the left.
ARE-1 and ARE-2 are novel protein/DNA
interactions detected by this assay. Open
head arrows indicate protected residues,
while closed head arrows indicate en-
hancements. A large bent arrow indicates
the site of transcription initiation. B, ul-
traviolet light-induced in vivo footprint-
ing. Sites of enhanced pyrimidine dimer
formation are indicated with arrows.
Lanes 1 and 2 are DMS in vivo footprint-
ing as in A for comparison. Lanes 3 and 4
are in vitro UV light-exposed control sam-
ples (50 or 200 3 100 J/m2). DNA isolated
after exposing live Raji B cells to UV light
(50 or 100 3 100 J/m2) is shown in lanes 5
and 6.
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containing potentially homologous known transcription factor
binding sites. Incubation of an oligonucleotide containing the
ARE-1 DNA element with nuclear extracts from B-lymphocytes
revealed two specific complexes (Fig. 6A). Formation of each of
the protein-DNA complexes was eliminated by the addition of a
50–100-fold molar excess of unlabeled ARE-1 oligonucleotide
(lane 1 versus lane 2). The upper two complexes are not B
cell-specific, since they are detected in multiple cell types (lanes
7–12). Competition with a mutated ARE-1 element or an oligo-
nucleotide containing the site C element did not alter the
binding pattern (lanes 3 and 6). A weak homology between
ARE-1 and the B cell-specific activator protein, BSAP (32), as
well as the Pu.1 transcription factor (39), was suggested by
comparison with the available transcription factor data bases
(40). A high affinity BSAP binding site from the CD19 promoter
(32) did not compete for the upper two complexes, but it weakly
blocked formation of the lower complex (lane 4). However,
co-transfection of a BSAP expression vector along with CIITA
promoter III reporter constructs containing a wild type or mu-
tated ARE-1 element did not alter the activity of the CIITA
promoter, while control promoter constructs were responsive to
BSAP overexpression.2 This finding indicates that BSAP is
unlikely to be the important factor bound at the ARE-1 element
in vivo. A consensus Pu.1 binding site oligonucleotide did not
compete for any of the ARE-1 complexes (lane 5). Homology
searches also indicated a 9 of 11 match with a region of the
SV40 promoter that contains overlapping binding sites for AP3
and TEF-2 (41, 42). In addition, an earlier study suggested
homology with a c-Myb or c-Myc binding sequence (10). To
directly test the significance of these binding site homologies, a
series of site-specific ARE-1 mutations were engineered in the
CIITA promoter III-luciferase construct and examined for the
loss of transcriptional activation in B cells (Table I). Elimina-
tion of the c-Myb/c-Myc homology (Mt4) or partial mutation of
the AP3 and TEF-2 sites (Mt3) did not significantly alter tran-
scriptional activity when compared with the parent constructs.
However, mutations (Mt1 and Mt2) that disrupt the central
sequence of 59-GGGAG-39 resulted in a loss of activity similar
to deletion of the entire domain (CIITAp3.113-Luc, Fig. 1). This
2 G. Wright, personal communication.
FIG. 3. Schematic of the sequence of CIITA promoter III and in
vivo protein/DNA interactions in B-lymphocytes. Open head ar-
rows (protections) and closed head arrows (enhancements) indicate in
vivo protein/DNA interactions observed after DMS treatment of cells.
Sites of ultraviolet light-induced enhancements of in vivo pyrimidine
dimer formation are denoted by V. The 59-end of each deletion construct
tested in Fig. 1 is indicated by a vertical bar and deletion number. The
transcription initiation site is indicated by 11.
FIG. 4. DNA/protein interactions at
the CIITA promoter III correlates
with CIITA and MHC class II expres-
sion in myeloma cell lines. A, semi-
quantitative reverse transcription PCR
demonstrates that NCI-H929 does not ex-
press CIITA or MHC class II mRNA,
while U266 expresses low levels of both. B
cell lines, Raji and IM9, are shown as
positive controls. To ensure the reactions
are in the linear range, each group of
three lanes represents PCR done with 0.5,
1.0, or 2.0 mg of starting cDNA material.
GAPDH was also amplified independ-
ently to control for the cDNA concentra-
tion and quality (data not shown). B,
DMS in vivo footprint analysis of CIITA
promoter III in myeloma cell lines. This
experiment is the same as in Fig. 2A ex-
cept lanes 1–4 are of the promoter in the
U266 cells, and lanes 5–8 are of the pro-
moter in the NCI-H929 cells. A nearly
identical pattern of contacts is observed
in the U266 line, while the NCI-H929 line
is completely devoid of in vivo contacts.
Lane markings are as described for
Fig. 2A.
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sequence is a 4 of 5 match to the TEF-2 core pentanucleotide.
To determine the relationship between the TEF-2 and ARE-1,
in vitro binding competitions were performed. The upper
ARE-1 protein-DNA complexes are competed with a TEF-2
consensus oligonucleotide (Fig. 6B). Upon using the TEF-2
consensus oligonucleotide as a DNA binding site probe, a
strong specific protein-DNA complex was observed (Fig. 6B).
Increasing the titration of competitor oligonucleotides demon-
strated that ARE-1 was only 20% as effective as the consensus
TEF-2 site in competing the TEF-2 complex. This indicates that
ARE-1 binding is related to the TEF-2 binding activity but is a
highly divergent and weak site. Interestingly, the presence of
strong in vivo protections in this region compared with the
weak binding observed in vitro suggests that the stability of the
complex may depend on its interactions with other proteins at
the CIITA promoter.
ARE-2 Binding Factor Is a Novel Transcriptional Activa-
tor—A similar series of experiments were performed to char-
acterize the ARE-2 binding factor(s) (Fig. 7). A single specific
complex is detected when an oligonucleotide containing the
ARE-2 element is incubated with B cell nuclear extracts. The
complex is abolished by the addition of a 50–100-fold molar
excess of an oligonucleotide containing the wild type ARE-2
sequence (lane 3). The addition of an oligonucleotide that con-
tains the ARE-2 element with the mutation, which dramati-
cally reduced transcriptional activity, did not compete for bind-
ing to this complex (lane 2). Because the ARE-2 element does
not have significant homology to any known transcription fac-
tors, a panel of potentially related and unrelated DNA binding
elements were used as competitors to test the specificity of the
complex (lanes 4–7). None of the oligonucleotides tested thus
far have any affinity for the ARE-2 binding complexes. The
analogous region from the mouse CIITA promoter III matches
8 of 11 nucleotides in the ARE-2 element; however, oligonu-
cleotides containing the murine sequence did not have any
affinity for the human ARE-2 complex (lane 4). The formation
of ARE-2 complexes is not limited to the B cell extracts and can
be detected in multiple cell types including lung, renal, and
colon (data not shown).
Site A Is Specifically Bound by NF-1, while Site B Weakly
Interacts with OTF-1—Site A and site B are located within the
first 45 base pairs upstream of the transcription start site and
were defined based on two clusters of weak in vivo interactions.
These sites were tested for specific factors binding in vitro. The
site A sequence formed one intense slow migrating complex
when incubated with a B cell nuclear extract (Fig. 8). This
complex was specifically eliminated by competition with a mo-
lar excess of site A oligonucleotide (lane 2) but not with the
mutated site A sequence or the ARE-1 oligonucleotide (lanes 3
and 5). Site A contains sequences with homology to the binding
site for NF-1 (30) and a weaker homology to the Sp1 binding
site (43). An oligonucleotide containing the consensus NF-1
binding sequence also eliminated the complex (lane 4) when
used as a competitor, but a consensus sequence for Sp1 binding
had no effect (data not shown). The consensus NF-1 oligonu-
cleotide forms a similar complex when it is used as the probe
(lane 6). Importantly, the putative NF-1 site in CIITA promoter
III can also effectively compete for this complex (lane 7). This
provides strong evidence that NF-1 is the factor bound at this
in vivo identified site of protein/DNA interaction.
Site B was previously suggested to be an octamer factor
FIG. 5. Site-directed mutagenesis demonstrates that the ARE-1
and ARE-2 DNA elements are critical for transcriptional activ-
ity of CIITA promoter III in Raji B cells. Mutations in the ARE-1
and ARE-2 regions decreased transcriptional activity by 4- and 19-fold,
respectively. Double and triple mutants involving the ARE-1 and
ARE-2 sites also demonstrate a significant decrease in activity. The X in
the promoter schematic diagram indicates the site of the mutation. The
results shown here are an average of four experiments with mean 6
S.E. Results are normalized to protein recovered, and the CIITAp3.545-
Luc activity is normalized at 100.
FIG. 6. ARE-1 is a TEF-2-like element. A, electrophoretic mobility
shift assays were performed using an oligonucleotide containing the
ARE-1 sequence element and Raji B cell nuclear extracts. Competitor
oligonucleotides were added to the binding reaction at a 50–100-fold
molar excess and are indicated above each lane. The two arrows indicate
the specific DNA-protein complexes. NS, nonspecific interaction. Lanes
7–12, ARE-1 complex present in multiple cell types. HT29 is a colon
carcinoma cell line; Caki1 and Caki2 are renal cell carcinoma lines;
NCI-H929 and U266 are myeloma cell lines. B, electrophoretic mobility
shift assays were performed as above using ARE-1 oligonucleotide
probe (lanes 1–3) and consensus TEF-2 oligonucleotide probe (lanes
4–8) with Raji B cell nuclear extract. Specific competitors and the molar
excess used are indicated above the lanes.
Regulation of CIITA Promoter III in B-lymphocytes 32347
binding site based on a 7 of 8 base pair homology to the
consensus sequence (10). However, only barely detectable lev-
els of octamer factor OTF-1 could be observed at site B (data
not shown). In comparison, strong binding of both OTF-1 and
OTF-2 octamer factors was observed when the previously char-
acterized MHC DRA octamer site was used as a probe in the
same assay. This indicates that site B has very low affinity for
octamer factors and is consistent with the weak in vivo inter-
actions detected and the lack of transcriptional activation from
this site.
DISCUSSION
In this report, we have characterized CIITA promoter III,
which has previously been demonstrated to be the transcrip-
tionally active promoter in B-lymphocytes (10, 16, 44). Our
results show that the first 319 base pairs of CIITA promoter III
are sufficient for basal transcriptional activity in B cells. Im-
portantly, we have now utilized in vivo genomic footprinting to
map the occupied promoter elements in intact B cells. Two
strong AREs have been mapped in the first 151 base pairs of
the promoter. In addition, the region between 2195 and 2319
base pairs conferred a small increase in activity (,2-fold), but
only two weak and isolated in vivo enhancements were de-
tected in this area. ARE-1 is located between 2143 to 2132
base pairs and contains a protein/DNA interaction identified by
both in vivo footprint analysis and in vitro binding studies. The
ARE-1 element has partial homology to several previously de-
scribed transcription factor binding sites. BSAP, a factor that is
expressed specifically in B cells and has a developmental ex-
pression pattern similar to CIITA, was present in one of the
three complexes capable of binding to ARE-1 in vitro. However,
overexpression of the BSAP protein in B cells did not alter
CIITA promoter III activity. Thus, BSAP is unlikely to play an
important role at the ARE-1 site or in CIITA transcription.
ARE-1 also contains partial homology to the binding site for the
ubiquitously expressed TEF-2 protein. Mutation of the pen-
tanucleotide core sequence but not the less well conserved
flanking region resulted in a loss of transcriptional activity.
TEF-2-like binding activity was detected in vitro at the ARE-1
sequence, but only with weak affinity compared with the con-
sensus TEF-2 site. Like ARE-1, TEF-2 has been shown to be a
transcriptional activator, present in multiple cell types (33).
TEF-2 belongs to the Kruppel family of transcription factors,
which include the erythroid factor EKLF and bind to CTCCC
motifs. CIITA may be activated specifically by TEF-2 or an-
other as yet unknown family member. Interestingly, this se-
quence motif is also conserved in the murine CIITA promoter
III sequence at an analogous position relative to the transcrip-
tion start site (10).
Another region critical for basal transcriptional activity is
the ARE-2 region located from 264 to 256 base pairs relative
to the transcription initiation site. The ARE-2 element does not
bear any homology to the binding site of any known transcrip-
tion factor. Mutation of this site nearly abolishes transcription;
FIG. 7. The ARE-2 sequence forms a single high affinity inter-
action in vitro. Electrophoretic mobility shift assays were performed
as in Fig. 6 except the probe contained the ARE-2 sequence. Competi-
tors are indicated above each lane. The murine ARE-2 competitor (lane
4) represents the sequence from the analogous region of the murine
CIITA promoter III. The arrow indicates the specific DNA protein
interaction.
FIG. 8. NF-1 binds to the CIITA promoter III in vitro. Raji
nuclear extract was incubated with either a radiolabeled CIITA pro-
moter III oligonucleotide containing the site A sequence (lanes 1–5) or a
consensus NF-1 binding site oligonucleotide (lanes 6–10). Lanes 1 and
6 have no competitor DNA added. Competitor oligonucleotides were
added to the binding reaction at a 50–100-fold molar excess and are
indicated above each lane. The arrow indicates the specific DNA protein
interaction.
TABLE I
The ARE-1 sequence element and four mutations
Transcriptional activity is the average luciferase activity per mg of protein lysate from three independent experiments. Each mutation was tested
independently with the appropriate wild type control, and the ratio is the value of activity of the mutant construct divided by the activity of the
parent wild type construct. Mt1 and Mt2 are in the context of the 545-base pair promoter while Mt3 and Mt4 are in the context of the 151-base




Mt1 -----------tctaga-------- 120 6 21.4 16.2 6 4.6 0.13
Mt2 --------cta-a------------ 120 6 7.9 36.5 6 2.3 0.30
Mt3 ---------------ctc------- 101 6 5.6 88.9 6 7.4 0.88
Mt4 --------tt--------------- 60.9 6 10.4 51.9 6 6.2 0.85
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therefore, the binding of a transcriptional activator to this site
is essential for basal CIITA transcription. Interestingly, the
sequence of the murine CIITA promoter III is not well con-
served compared with the human sequence in this area. In-
deed, the murine sequence did not compete with the human
sequence for the ARE-2 binding factor. This indicates that in
contrast to ARE-1, a role for the ARE-2 binding factor may only
be present at the human CIITA promoter III.
Undoubtedly, the factors bound at ARE-1 and ARE-2 are
critical for CIITA transcription and thus MHC class II expres-
sion in B-lymphocytes. However, their role in determining the
B cell specificity of the promoter is not clear. Both of these
factors are present in extracts derived from all cell types tested
such as lung, colon, and kidney. However, this finding does not
exclude them from being functionally regulated in a B cell-
specific manner. It is possible that these factors need to be
activated by coactivators, which may be present only during
certain stages of B cell development analogous to the interac-
tion of OTF-1 and its coactivator BOB-1 (45). The simplest
mechanism of establishing B cell specificity through binding of
OTF-2/BOB1 or OTF-1/BOB1 (46) is unlikely to play a role in
CIITA B cell specificity. The only putative octamer binding site
in the promoter is present at site B and does not activate
transcription or bind either OTF-1 or OTF-2 with significant
affinity.
Site A, located 12 base pairs upstream of the transcription
start site, has been demonstrated to bind the transcription
factor NF-1. NF-1 is involved in both transcriptional activation
and replication (47, 48). It binds as a dimer to the recognition
site TGG(C/A)N5GCCAA. We observe partial protection of site
A in vivo, although there is a two-base pair mismatch (lower-
case type) with the consensus sequence (TGGg(C/A)N5cCCAA).
In vitro DNA binding as examined by electrophoretic mobility
shift assay demonstrated strong specific binding of NF-1 to site
A. Surprisingly, mutation of this site did not alter transcrip-
tional activity. However this finding does not exclude a role for
NF-1 in CIITA transcription in vivo. NF-1 has been previously
demonstrated to bind near the initiation site of several TATA-
less promoters such as the mouse complement C4 promoter and
the AP2 promoter (49, 50). NF-1 may play an important role in
transcription start site selection. The CIITA promoter III also
lacks a TATA box and yet predominantly initiates transcription
from a single site 12 base pairs downstream of the NF-1 site.
Interestingly, a previous report proposed an initiator element
located at approximately 60 base pairs upstream of the initia-
tion site; however, the site was not tested by the authors (44).
Their proposed initiator overlaps with the ARE-2 transcrip-
tional activator element. The functional significance of NF-1
binding and the mechanism of start site selection at CIITA
promoter III remains to be determined.
When B-lymphocytes terminally differentiate to plasma
cells, MHC class II expression is down-regulated. However, in
plasmacytoma cell lines, the level of MHC class II on the cell
surface varies from low to absent. Our examination of two
representative plasmacytoma cell lines indicates, as predicted,
that the level of MHC class II expression is correlated with the
level of CIITA expression. In vivo genomic footprinting reveals
that in CIITA-negative plasmacytoma cell lines the entire CI-
ITA promoter III is unoccupied, while in CIITA-low cell lines
full promoter occupancy is maintained. This suggests that par-
tial suppression of CIITA transcription potentially in the early
stages of differentiation may be mediated through down-regu-
lation of the activity of established promoter complexes. In
contrast, complete disassembly of the CIITA promoter and an
alteration of the chromatin structure accompany complete re-
pression of CIITA transcription in terminally differentiated
plasma cells.
In conclusion, we have characterized the CIITA promoter in
B-lymphocytes and identified two predominant activation ele-
ments. Importantly, ARE-1 appears to bind a TEF-2-like factor,
and ARE-2 binds a novel transcription factor, both of which are
likely to play a significant role in MHC class II expression.
Knowledge of these activators is key to efforts directed at
manipulating MHC class II expression such as in reactivation
of expression in multiple myeloma and other MHC class II
negative cells in order to increase their immunogenicity.
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